Predictive value of Ki-67 expression in predicting pathological response to neoadjuvant chemotherapy combined with immunotherapy in lung squamous cell carcinoma - Report - MDSpire
Advertisement
Predictive value of Ki-67 expression in predicting pathological response to neoadjuvant chemotherapy combined with immunotherapy in lung squamous cell carcinoma
Clinical Report: Evaluating the Role of Ki-67 Expression as a Predictor of Pathological Response to Neoadjuvant Chemoimmunotherapy in Lung Squamous Cell Carcinoma
Overview
This study evaluates Ki-67 expression as a predictive biomarker for pathological response in patients with lung squamous cell carcinoma undergoing neoadjuvant chemoimmunotherapy.
Background
Neoadjuvant chemoimmunotherapy is becoming standard for locally advanced lung squamous cell carcinoma, yet reliable predictive biomarkers for treatment response are still needed. Ki-67, a marker of cellular proliferation, has shown potential in predicting responses in advanced disease, but its role in the neoadjuvant setting remains unclear.
Data Highlights
Parameter
Value
MPR/pCR Rate
56.2% (77/137 patients)
Optimal Ki-67 Cutoff
55%
AUC
0.785 (95% CI: 0.707–0.862)
High Ki-67 MPR/pCR Rate
69.6%
Low Ki-67 MPR/pCR Rate
27.9%
Key Findings
MPR/pCR was achieved in 56.2% of patients (77/137).
Optimal Ki-67 cutoff for predicting MPR/pCR was determined to be 55%.
High Ki-67 expression (≥55%) was associated with a significantly higher MPR/pCR rate (69.6% vs. 27.9%, P<0.001).
In multivariate analysis, Ki-67 expression and smoking status were independent predictors of MPR/pCR.
PD-L1 expression did not show a significant association with MPR/pCR (P = 0.607).
Clinical Implications
Understanding the role of smoking status alongside Ki-67 could further refine patient selection for neoadjuvant therapies.
Conclusion
Further validation in prospective studies is necessary before clinical implementation.
